PubMed Health⌕ Search

PubMed · 16068178

A major difference between transdetermination and homeosis.

Abstract

IN Drosophila, the adult structures arise from nests of larval cells called imaginal disks, whose state of determination with respect to disk type is usually fixed. However, two processes are known which can change determination from one disk type to another; one occurs in situ and is due to homeotic mutations, and the other is seen after culture of disk material and is called transdetermination. Similarities between the two, notably the lack of intermediate states, have led to the idea that they are different aspects of the same phenomenon(1,2). The existence of homeotic mutations argues that determination in normal development is underlain by a genetic switching mechanism(3,4); transdetermination could result from epigenetic changes in this system. If this is so then the two phenomena should have characteristics in common. Studies of homeotic mutants have shown that a structure in one disk is always transformed into a specific structure from the other disk(5,6); for example clones of bithorax in an anterior dorsal position in the haltere show anterior dorsal wing structures(5). This is used as a criterion of homology, and also indicates that all disks use the same positional information(7). Differences between disks must be due to different interpretation of this information, mediated in some way by the wild-type alleles of the homeotic genes. It is not yet known whether transdetermination also shows position-specific transformation; if the two phenomena are closely related then this should be the case. It is often assumed to be so, because there have been reports of transdetermination between leg and antenna in which structures such as claw and arista, thought from homeotic mutants to be homologous, are found adjacent to one another in implants(1). However, these findings could also be explained by non-homologous transdetermination followed by either movement together of homologous structures due to preferential cell affinities, or intercalary regeneration between the non-homologous structures. Also, regeneration before transdetermination can give misleading results. One cannot simply ask to what structures a given disk fragment will transdetermine as the fragment might regenerate the rest of the disk first, and non-regenerating (that is duplicating) fragments do not appear to transdetermine (unpublished observations, and ref. 8). One solution to these problems is to find a disk in which transdetermination occurs only in one part, and this is the case in the foreleg disk. The experiments reported here were designed to find whether this part transdetermines to a homologous part of the wing disk.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Karlsson. 1979-05-31. A major difference between transdetermination and homeosis.. https://doi.org/10.1038/279426a0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗